{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:18:14Z","timestamp":1792603094945,"version":"4.5.0"},"reference-count":21,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  BACKGROUND:  The interaction between serum lipids and C virus infection is well known, as are serum lipid levels in the Peg-IFN \/ RBV-based treatment. However, with direct action antivirals (DAAs) this behavior is still unclear.  OBJECTIVE:  To compare serum lipids levels between patients treated with Peg-IFN\/RBV and DAAs and to evaluate lipids in sustained virological response (SVR) with DAAs.  METHODS:  Retro prospective study comparing the behavior of total cholesterol (TC), low-density lipoprotein (LDL) and triglycerides (TG) serum levels during treatment with DAAs (G-DAAs) and a control historic group Peg-IFN\/RBV (G-PR). Coorte, prospective study, to study the behavior of lipids in the SVR with DAAs. Data were collected at the beginning of treatment (baseline: t-base) and at week 12 of treatment (t-12) for G-DAAs and at week 24 (t-24) for G-PR, groups. In the cohort evaluation, the samples at t-base and at week 12 after the end of treatment (t-SVR). Delta lipids: difference between lipids in t-12 \/ t-24 minus t-base for comparison between G-PR and G-AADs groups and t-SVR minus t-base for lipid analysis in SVR. Analysis with Kruskal Wallis and Wilcoxon tests to compare the delta lipids of the groups. The P value was 0.05.  RESULTS:  In the assessment between G-PR and G-DAAs groups, we included 63 and 121 patients, respectively. The groups did not differ one from the other (BMI, sex, genotype, fibrosis, total cholesterol, LDL, and TG) except by age (50.38\u00b110.44 vs 56\u00b19.69, P=0.0006). We observed a decrease in levels of TC and LDL and an increase in TG, in G-PR, and in G-DAAs the opposite (\u0394 TC -13.9\u00b134.5 vs 4.12\u00b134.3 P=0.0005, \u0394 LDL -7.16\u00b132 vs 10.13\u00b129.92, P=0.003, \u0394 TG 4.51\u00b153.7 vs -8.24\u00b149.93, P=0.0025). In the coorte analysis, we included 102 patients, 70% men and 56% F4, 95 of them reached SVR. We observed an increase of TC and LDL and a decrease of TG in both groups (SVR and non SVR), with no statistical difference (\u0394 TC P=0.68; \u0394 LDL P=0.69; \u0394 TG P=0.43). We did not find significant difference in delta evaluation by genotype 1 and 3 (\u0394 TC +29.7\u00b140.2 vs +13.4\u00b130.3, P=0.06; \u0394 LDL +21.4\u00b128.6 vs +16.6\u00b131.3, P=0.41; \u0394 TG -3.6\u00b160.6 vs -0.7\u00b140, P=0.91).  CONCLUSION:  Serum lipids level differed during treatment with Peg-IFN and DAAs. Treatment with DAAs was associated with an increase of TC and LDL and a decrease of TG, independently of SVR.<\/jats:p>","DOI":"10.1590\/s0004-2803.201800000-33","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T18:56:39Z","timestamp":1532717799000},"page":"184-187","source":"Crossref","is-referenced-by-count":11,"title":["INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?"],"prefix":"10.1590","volume":"55","author":[{"given":"Vanessa Gutierrez de","family":"ANDRADE","sequence":"first","affiliation":[{"name":"Universidade Estadual Paulista J\u00falio de Mesquita Filho,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio da Silva","family":"YAMASHIRO","sequence":"additional","affiliation":[{"name":"Universidade Estadual Paulista J\u00falio de Mesquita Filho,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassio Vieira","family":"OLIVEIRA","sequence":"additional","affiliation":[{"name":"Universidade Estadual Paulista J\u00falio de Mesquita Filho,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia Last\u00f3ria","family":"KUROZAWA","sequence":"additional","affiliation":[{"name":"Universidade Estadual Paulista J\u00falio de Mesquita Filho,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alecsandro","family":"MOREIRA","sequence":"additional","affiliation":[{"name":"Universidade Estadual Paulista J\u00falio de Mesquita Filho,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Faria","family":"SILVA","sequence":"additional","affiliation":[{"name":"Universidade Estadual Paulista J\u00falio de Mesquita Filho,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2018,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy D","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","article-title":"Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis","volume":"134","author":"Moucari R","year":"2008","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/gut.2009.192732","article-title":"Abnormalities of lipid metabolism in hepatitis C virus infection","volume":"59","author":"Negro F","year":"2010","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2000-9506","article-title":"Epidemiology of hepatitis C: geographic differences and temporal trends","volume":"20","author":"Wasley A","year":"2000","journal-title":"Semin Liver Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.1840120409","article-title":"Interrelationship of blood transfusion, non A, non B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus","volume":"12","author":"Kiyosawa K","year":"1990","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2000-9505","article-title":"Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on longterm outcome","volume":"20","author":"Alter HJ","year":"2000","journal-title":"Semin Liver Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3748\/wjg.v22.i4.1461","article-title":"Metabolic alterations and hepatitis C: from bench to bedside","volume":"22","author":"Chang ML","year":"2016","journal-title":"World J Gastroenterol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1128\/JVI.76.14.6919-6928.2002","article-title":"Characterization of low- and very-low-density hepatitis C virus RNA-containing particles","volume":"76","author":"Andr\u00e9 P","year":"2002","journal-title":"J Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"9647","DOI":"10.1128\/JVI.00914-08","article-title":"Apolipoprotein c1 association with hepatitis C virus","volume":"82","author":"Meunier JC","year":"2008","journal-title":"J Virol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"13783","DOI":"10.1128\/JVI.01091-07","article-title":"Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture","volume":"81","author":"Chang KS","year":"2007","journal-title":"J Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.23278","article-title":"Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles","volume":"51","author":"Benga WJ","year":"2010","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/hep.23796","article-title":"Virahep-C Study Group. Associations between serum lipids and hepatitis C antiviral treatment efficacy","volume":"52","author":"Ramcharran D","year":"2010","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2893.2010.01394.x","article-title":"Serum lipids and their associations with viral levels and liver disease severity in a treatment-na\u00efve chronic hepatitis C type 1-infected cohort","volume":"18","author":"Ramcharran D","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5144\/0256-4947.2015.293","article-title":"Improvement of glucose and lipid metabolism with pegylated interferon-\u03b1 plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus","volume":"35","author":"Qing S","year":"2015","journal-title":"Ann Saudi Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.23219","article-title":"Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up","volume":"50","author":"Corey KE","year":"2009","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.27424","article-title":"Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients","volume":"61","author":"Meissner EG","year":"2015","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3748\/wjg.v23.i13.2355","article-title":"Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b","volume":"23","author":"Endo D","year":"2017","journal-title":"World J Gastroenterol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.4254\/wjh.v8.i35.1557","article-title":"Hepatitis C eradication with sofosbuvir leads to significant metabolic changes","volume":"8","author":"Morales AL","year":"2016","journal-title":"World J Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"10226","DOI":"10.3748\/wjg.v22.i46.10226","article-title":"Genotype specific peripheral lipid profile changes with hepatitis C therapy","volume":"22","author":"Pedersen MR","year":"2016","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1097\/MCG.0b013e31826102eb","article-title":"Intensified Peginterferon a-2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein","volume":"47","author":"Harrison SA","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2893.2004.00528.x","article-title":"Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections","volume":"11","author":"H\u00e9zode C","year":"2004","journal-title":"J Viral Hepat"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v55n2\/1678-4219-ag-55-02-184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T16:00:21Z","timestamp":1536163221000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032018000200184&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["S0004-28032018000200184"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.201800000-33","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}